NCT01187303已完成2 期
Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Overall response rate
研究概览
简要总结
The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •relapsed nodular lymphocyte predominant hodgkin lymphoma
- •age 18 - 75
- •review of diagnosis by experienced pathologist
- •no major organ dysfunction
排除标准
- •classical hodgkin lymphoma
- •CD20 antibody treatment within the last 6 months prior enrollment
- •chronic or current infectious disease requirering systemic antibiotics
- •other past or current malignancy
结局指标
主要结局
Overall response rate
时间窗: 12 months after end of treatment
次要结局
- adverse events(12 months after end of treatment)
- duration of response(12 months after end of treatment)
- Progression free survival(12 months after end of treatment)
研究者
Prof. Dr. Andreas Engert
Prof.
University of Cologne
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphomarelapsed nodular lymphocyte predominat Hodgkin LymphomaMedDRA version: 12.1Level: LLTClassification code 10020227Term: Hodgkin's disease lymphocyte predominance type recurrentEUCTR2010-022180-35-DEniversity of Cologne
终止
2 期
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance TherapyLymphomaLeukemiaNCT01258933M.D. Anderson Cancer Center4
已完成
2 期
Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B-cell LymphomaNCT02412267National Cancer Centre, Singapore17
已完成
2 期
Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large Cell Lymphoma Relapsed/RefractoryNCT01555541C. Babis Andreadis19
已完成
4 期
Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)Leukaemia, Lymphocytic, ChronicNCT00802737GlaxoSmithKline29